Directing cancer drugs to their target is a mainstay of the drug-delivery industry, and researchers in Australia and the U.K. may have found a way to enhance imaging of drugs' release at tumor sites, helping to target them where they lie.
Researchers at the University of Cambridge are talking up the potential of a vaccine to stop traveler's diarrhea.
Researchers at Boston Children's Hospital have identified a biomarker that could help match the right stem cell line to patients to more effectively treat a variety of cancers.
In its $1.15 billion buyout of Pearl Therapeutics this week, AstraZeneca bolstered its late-stage drug development with a Phase III inhaled delivery platform to treat respiratory diseases.
According to analysts, the Alzheimer's drug market peaked last year at $10.2 billion and will now slide 1.5% per year until 2017, when the cash returns will slide to about $9.5 billion.
Last month, Millennium CEO Deborah Dunsire stepped down and company veteran Anna Protopapas stepped in as president of the company, which will no longer operate as autonomously as it had before the reorganization. The reorganization will also come at the expense of an undisclosed number of jobs.
An investigative team of heart experts has tracked down a pair of biomarkers they say can flag people who are at risk of having "silent strokes," asymptomatic events that can quietly damage the brain and leave them threatened by even worse incidents of heart and vascular disease.
Calling everyone from the global biotech community. We've begun seeking nominations for FierceBiotech 's 2013 class of Fierce 15 companies, and our editors would like to give readers a voice in the selection process. It's really easy: Just fill out our online nomination form here.
Lemtrada, Sanofi's "new" drug for multiple sclerosis, helps demonstrate just how plagued the drug-development process can be, with a series of false starts and sudden stops as it was handed off from one company to the next. Today, Reuters ' Ben Hirschler chronicled the 25-year R&D odyssey, which is expected to be capped soon with a European approval followed soon after by an FDA decision.
After whetting analysts' expectations on the deal-making front, he executed a series of small deals for experimental ophthalmology treatments--which fit well with his own professional background.